ZA200305326B - Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. - Google Patents

Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists.

Info

Publication number
ZA200305326B
ZA200305326B ZA200305326A ZA200305326A ZA200305326B ZA 200305326 B ZA200305326 B ZA 200305326B ZA 200305326 A ZA200305326 A ZA 200305326A ZA 200305326 A ZA200305326 A ZA 200305326A ZA 200305326 B ZA200305326 B ZA 200305326B
Authority
ZA
South Africa
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
ZA200305326A
Other languages
English (en)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of ZA200305326B publication Critical patent/ZA200305326B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ZA200305326A 2001-04-30 2003-07-10 Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. ZA200305326B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ZA200305326B true ZA200305326B (en) 2003-07-30

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200305326A ZA200305326B (en) 2001-04-30 2003-07-10 Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists.

Country Status (28)

Country Link
US (1) US7288517B2 (xx)
EP (1) EP1392348B1 (xx)
JP (1) JP2004529207A (xx)
KR (1) KR20040000446A (xx)
CN (1) CN1317030C (xx)
AT (1) ATE400287T1 (xx)
AU (1) AU2002310788B2 (xx)
BG (1) BG108339A (xx)
BR (1) BR0209290A (xx)
CA (1) CA2444876A1 (xx)
CZ (1) CZ20033167A3 (xx)
DE (1) DE60227507D1 (xx)
DK (1) DK1392348T3 (xx)
ES (1) ES2307760T3 (xx)
HK (1) HK1072000A1 (xx)
HU (1) HUP0400067A2 (xx)
IL (1) IL156777A0 (xx)
MX (1) MXPA03008666A (xx)
NO (1) NO20034322L (xx)
NZ (1) NZ544417A (xx)
PL (1) PL362319A1 (xx)
PT (1) PT1392348E (xx)
RU (1) RU2319501C2 (xx)
SI (1) SI1392348T1 (xx)
SK (1) SK14512003A3 (xx)
UA (1) UA80679C2 (xx)
WO (1) WO2002102401A1 (xx)
ZA (1) ZA200305326B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
KR100748294B1 (ko) 2000-07-05 2007-08-09 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
MXPA06014131A (es) * 2004-06-04 2007-03-07 Astellas Pharma Inc Derivado de propano-1,3-diona o su sal.
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
PT1864976E (pt) * 2005-03-31 2013-01-04 Astellas Pharma Inc Derivado de propano-1,3-diona ou um seu sal
JP5406030B2 (ja) * 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
US20100197601A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
RU2010113975A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
WO2009145690A1 (en) * 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
WO1997044339A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
CA2372044A1 (en) * 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
JP2003512379A (ja) * 1999-10-15 2003-04-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
EP1393747A1 (en) 2000-04-13 2004-03-03 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
KR100748294B1 (ko) * 2000-07-05 2007-08-09 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체

Also Published As

Publication number Publication date
SK14512003A3 (sk) 2004-08-03
EP1392348B1 (en) 2008-07-09
PL362319A1 (en) 2004-10-18
ES2307760T3 (es) 2008-12-01
JP2004529207A (ja) 2004-09-24
WO2002102401A1 (en) 2002-12-27
NO20034322D0 (no) 2003-09-26
CN1317030C (zh) 2007-05-23
CZ20033167A3 (cs) 2004-08-18
HK1072000A1 (en) 2005-08-12
DE60227507D1 (de) 2008-08-21
NZ544417A (en) 2008-03-28
RU2003134949A (ru) 2005-02-10
PT1392348E (pt) 2008-09-09
US7288517B2 (en) 2007-10-30
BR0209290A (pt) 2004-07-13
EP1392348A1 (en) 2004-03-03
HUP0400067A2 (hu) 2004-04-28
IL156777A0 (en) 2004-02-08
AU2002310788B2 (en) 2007-04-05
BG108339A (bg) 2004-11-30
ATE400287T1 (de) 2008-07-15
RU2319501C2 (ru) 2008-03-20
SI1392348T1 (sl) 2008-12-31
NO20034322L (no) 2003-09-26
MXPA03008666A (es) 2004-10-15
KR20040000446A (ko) 2004-01-03
CN1575185A (zh) 2005-02-02
CA2444876A1 (en) 2002-12-27
UA80679C2 (en) 2007-10-25
US20020177556A1 (en) 2002-11-28
DK1392348T3 (da) 2008-09-29

Similar Documents

Publication Publication Date Title
HK1072000A1 (en) Treatment of alzheimer's diseases with intemediatedoses of lhrh antagonists
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
MY134906A (en) Prevention and treatment of amyloidogenic disease
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MY136707A (en) Thrombopoietin mimetics
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GB0223040D0 (en) Therapeutic compounds
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
NO20004432L (no) Glysintransportinhibitorer
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
MY124786A (en) Bis-arylsulfones
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG105651A (en) Vitronectin receptor antagonist
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
WO2002062383A3 (en) Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
MXPA04000870A (es) Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease